Sherbrooke Park Advisers LLC Catalyst Pharmaceuticals, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $436 Billion
- Q3 2024
A detailed history of Sherbrooke Park Advisers LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 15,914 shares of CPRX stock, worth $367,454. This represents 0.07% of its overall portfolio holdings.
Number of Shares
15,914
Previous 11,635
36.78%
Holding current value
$367,454
Previous $180 Million
75.54%
% of portfolio
0.07%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding CPRX
# of Institutions
334Shares Held
95.4MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$432 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$186 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$144 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$131 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$69.7 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.37B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...